Failure on First-Line Lopinavir/r Monotherapy: High Rates of PI Resistance
Results from the MONARK trial do not support lopinavir/r monotherapy as first-line treatment for HIV infection, because it was both less effective and more likely to cause major PI resistance than triple therapy with lopinavir/r, AZT, and 3TC.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)